The results of survival analysis showed that the survival rate of the low-expression group of ESR1 and MMP2 was higher than that of the high-expression group, which further confirmed that reducing the expression of ESR1 and MMP2 could improve the quality of life of NSCLC patients. This evidence concerns the gene MMP2 and non-small cell lung carcinoma.